Recent studies have now demonstrated that patients with MMR‐deficient pancreatic cancer have earlier onset tumors, distinct histological patterns, increased immunogenicity, improved response to immunotherapies, and longer overall survival when compared to MMR‐proficient pancreatic cancer (as shown in Table 3). This evidence concerns the gene MRC1 and familial pancreatic carcinoma.